ES2188585T3 - Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices. - Google Patents

Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.

Info

Publication number
ES2188585T3
ES2188585T3 ES92925260T ES92925260T ES2188585T3 ES 2188585 T3 ES2188585 T3 ES 2188585T3 ES 92925260 T ES92925260 T ES 92925260T ES 92925260 T ES92925260 T ES 92925260T ES 2188585 T3 ES2188585 T3 ES 2188585T3
Authority
ES
Spain
Prior art keywords
methods
decorin
protein
factor
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92925260T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Michael T Longaker
David J Whitby
John R Harper
Michael D Pierschbacher
Wayne A Border
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WHITBY DAVID J DR
Sanford Burnham Prebys Medical Discovery Institute
University of Utah
University of California Berkeley
University of California San Diego UCSD
Original Assignee
WHITBY DAVID J DR
Sanford Burnham Prebys Medical Discovery Institute
University of Utah
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WHITBY DAVID J DR, Sanford Burnham Prebys Medical Discovery Institute, University of Utah, University of California Berkeley, University of California San Diego UCSD filed Critical WHITBY DAVID J DR
Application granted granted Critical
Publication of ES2188585T3 publication Critical patent/ES2188585T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN METODO DE INHIBICION DE UNA ACTIVIDAD DE UN FACTOR REGULADOR DE LAS CELULAS QUE COMPRENDE EL CONTACTO DEL FACTOR REGULADOR DE LAS CELULAS CON UN POLIPEPTIDO PURIFICADO, EN EL CUAL EL POLIPEPTIDO COMPRENDE EL CAMPO DE ENLACE DEL FACTOR REGULADOR DE LAS CELULAS DE UNA PROTEINA Y EN EL CUAL LA PROTEINA ESTA CARACTERIZADA POR UNA REPETICION RICA EN LEUCINA DE APROXIMADAMENTE 24 AMINOACIDOS. EN UNA REALIZACION ESPECIFICA, LA PRESENTE INVENCION SE REFIERE A LA CAPACIDAD DE DECORIN, UNA PROTEINA DALTON 40.000 QUE USUALMENTE LLEVA UNA CADENA GLICOSAAMINOGLICANO, PARA ENLAZAR TGF- . LA INVENCION TAMBIEN PROPORCIONA UN NUEVO FACTOR REGULADOR DE LAS CELULAS DESIGNADO MRF. TAMBIEN SE DESCRIBEN METODOS DE IDENTIFICACION, DETECCION Y PURIFICACION DE FACTORES REGULADORES DE LAS CELULAS Y PROTEINAS QUE ENLAZAN Y AFECTAN A LA ACTIVIDAD DE FACTORES REGULADORES DE LAS CELULAS. LA PRESENTE INVENCION DESCRIBE ADEMAS METODOS PARA LA PREVENCION O REDUCCION DE CICATRICES POR ADMINISTRACION DE DECORIN O DE UN EQUIVALENTE FUNCIONAL DE DECORINA A UNA HERIDA. LOS METODOS SON PARTICULARMENTE UTILES PARA HERIDAS DE LA PIEL RESULTANTES DE QUEMADURAS, HERIDAS O CIRUGIA. ADEMAS, LA PRESENTE INVENCION INCLUYE COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DECORINA O SU EQUIVALENTE FUNCIONAL Y UN PORTADOR ACEPTABLE FARMACEUTICAMENTE UTIL EN TALES METODOS. FINALMENTE, TAMBIEN SON DESCRITOS METODOS PARA LA PREVENCION O INHIBICION DE CONDICIONES PATOLOGICAS POR ADMINISTRACION DE DECORIN.
ES92925260T 1991-11-14 1992-11-13 Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices. Expired - Lifetime ES2188585T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79219291A 1991-11-14 1991-11-14
US88234592A 1992-05-13 1992-05-13

Publications (1)

Publication Number Publication Date
ES2188585T3 true ES2188585T3 (es) 2003-07-01

Family

ID=27121246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92925260T Expired - Lifetime ES2188585T3 (es) 1991-11-14 1992-11-13 Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.

Country Status (10)

Country Link
EP (2) EP0667784B1 (es)
JP (1) JPH07504886A (es)
AT (1) ATE233568T1 (es)
AU (1) AU673506B2 (es)
CA (1) CA2123418A1 (es)
DE (1) DE69232946T2 (es)
ES (1) ES2188585T3 (es)
FI (1) FI942244A7 (es)
NO (1) NO941821L (es)
WO (1) WO1993009800A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
WO1994020512A2 (en) * 1993-03-01 1994-09-15 Glycan Pharmaceuticals, Inc. Analogs for specific oligosaccharide-protein interactions and uses therefor
JPH09505057A (ja) * 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2002068647A2 (en) * 2001-01-16 2002-09-06 Curagen Corporation Proteins, polynucleotides encoding them and methods of using the same
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CN1506042A (zh) 2002-12-11 2004-06-23 苏加璐 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP2862867A3 (en) 2005-10-25 2015-08-05 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2009135135A2 (en) * 2008-05-01 2009-11-05 Chia Soo Fibromodulin formulation for reducing corneal scarring
KR100983182B1 (ko) 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
EP3456837A3 (en) * 2011-03-14 2019-04-24 Catalent Pharma Solutions, LLC Decorin compositions and use thereof
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
EP2989208A4 (en) 2013-04-22 2016-12-07 Catalent Pharma Solutions Llc DECORINAL COMPOSITIONS FOR VETERINARY MEDICINE AND USE THEREOF
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
JP2026504137A (ja) * 2023-01-27 2026-02-03 アロア・バイオサージェリー・リミテッド 組織虚血並びに関連した疾患及び容態を処置するための方法及び薬剤
WO2024158300A1 (en) * 2023-01-27 2024-08-02 Aroa Biosurgery Limited Methods and agents for treating soft tissue inflammation and associated diseases and conditions
AU2024212702A1 (en) * 2023-01-27 2025-08-21 Aroa Biosurgery Limited Methods and agents for treating respiratory inflammation and associated diseases and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2887325B2 (ja) * 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
AU628910B2 (en) * 1988-12-20 1992-09-24 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing

Also Published As

Publication number Publication date
FI942244A7 (fi) 1994-07-06
WO1993009800A1 (en) 1993-05-27
JPH07504886A (ja) 1995-06-01
FI942244A0 (fi) 1994-05-13
EP0667784B1 (en) 2003-03-05
AU3138593A (en) 1993-06-15
DE69232946T2 (de) 2003-12-18
NO941821D0 (no) 1994-05-13
EP1230929A1 (en) 2002-08-14
NO941821L (no) 1994-07-14
DE69232946D1 (de) 2003-04-10
AU673506B2 (en) 1996-11-14
CA2123418A1 (en) 1993-05-27
ATE233568T1 (de) 2003-03-15
EP0667784A1 (en) 1995-08-23

Similar Documents

Publication Publication Date Title
ES2188585T3 (es) Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
US8110655B2 (en) Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
EA200001258A1 (ru) Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
PT689550E (pt) Peptidos antimicrobianos de neutrofilos bovinos
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
ES2123134T3 (es) Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos.
US20180296456A1 (en) Decapeptide-12 Modulation of Sirtuin Gene Expression in Epidermal Keratinocyte Progenitors
EA200500804A1 (ru) Топические противоинфекционные композиции
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
AR044209A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
Bilic et al. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice
SE9503679D0 (sv) Antioxidants
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
JP6900324B2 (ja) 抗微生物ペプチド
KR101472476B1 (ko) 콜라겐 합성능이 있는 신규 펩타이드 유도체 및 그의 용도
MX9305901A (es) Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
EP0137743A3 (en) Topically administrable pharmaceutical compositions
ATE125571T1 (de) Interleukin-1-inhibitor.
ATE276272T1 (de) Entzündungshemmende peptide
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
KR20210116493A (ko) 인간 신생아 각질형성세포 전구체에서 면역억제 활성을 갖는 티로신 억제제